Sovaldi, the $1,000-a-day pill for hepatitis C – “The Centers for Disease Control and Prevention estimates that 3.2 million people in the U.S. have chronic hepatitis C infections. Most of them haven’t been diagnosed.”

A recent NPR story http://www.npr.org * reported that “Sovaldi is the first hepatitis C pill that doesn’t have to be accompanied by interferon for some types of hepatitis.”
“Sovaldi has been found to be remarkably effective, essentially curing 90 percent or more patients with a common form of hepatitis C in 12 weeks.”
“The Food and Drug Administration approved the pill in December. And then Gilead Sciences was off to the races. The company said it sold $2.27 billion worth of Sovaldi in the quarter that ended March 31. $2.27 billion!”
* to read the full NPT story” Costly Hepatitis C Pill Shreds Drug Industry Sales Record by Scott Hensley highglight and click on open hyperlink http://www.npr.org/blogs/health/2014/04/23/306236511/costly-hepatitis-c-pill-shreds-drug-industry-sales-record?utm_campaign=KHN%3A+First+Edition&utm_source=hs_email&utm_medium=email&utm_content=12588589&_hsenc=p2ANqtz-_b4XA_5N7ZUKrSGl8ZukZtv6wD4iidLaAdC8Ejigzz6f8zWSvr9Yk05qWhe5e5HcieX0MYvz0E0qKR_gLnu4OJu9Wwvhy33n01pta9CuBt4wn_5ZM&_hsmi=12588589
Note: This blog shares general information about understanding and navigating the health care system. For specific medical advice about your own problems, issues and options talk to your personal physician.